Skip to main content

Approved Metabolic & Obesity Deal Benchmarks

Median Upfront
$4.0B
Range: $3.0B - $4.8B
Total Deal Value
$10.5B
Range: $8.9B - $12.0B
Royalty Rate
24.3% - 30%
Tiered up to 35%
Dev Milestones
$321M
Range: $295M - $363M

Market Analysis

Approved metabolic & obesity licensing deals carry a median total deal value of $10.5B, with upfront payments ranging from $3.0B to $4.8B. At this stage, deal structures are shifted toward higher upfront allocations, reflecting reduced regulatory risk and near-term commercial potential. The recommended split allocates 39% to upfront and 61% to milestones.

The metabolic & obesity landscape at the approved stage is characterized by extremely high competitive intensity driven by the GLP-1 revolution and massive obesity market opportunity. Development milestones average $321M, regulatory milestones contribute $643M, and commercial milestones reach $5.5B. Oral formulations, dual/triple incretins, and muscle-sparing approaches command unprecedented deal valuations.

Royalty rates for approved metabolic & obesity deals range from 24.3% to 30% at the base tier, with high-tier escalation to 35%. The reduced risk profile at this stage justifies higher fixed royalty commitments.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for approved metabolic & obesity deals?
Approved metabolic & obesity deals average $4.0B in upfront payments, ranging from $3.0B to $4.8B. The upfront allocation of 39% of total deal value reflects the clinical stage risk profile.
How are approved metabolic & obesity deal milestones structured?
Milestones account for approximately 61% of total deal value. Development milestones ($321M) represent the largest component, followed by commercial milestones ($5.5B) and regulatory milestones ($643M).
What royalty rates are typical for approved metabolic & obesity licensing?
Base royalty rates range from 24.3% to 30%, with tiered escalation to 28.3%-35% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included